KalVista clears international regulatory hurdles on HAE trial; Elixiron raises $27M in Series A
Five months after KalVista was staggered by an FDA clinical hold on its Phase II trial for KVD824, their oral drug to treat attacks caused …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
